• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Previous Issues
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Egyptian Journal of Histology
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 48 (2025)
Volume Volume 47 (2024)
Volume Volume 46 (2023)
Volume Volume 45 (2022)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 44 (2021)
Volume Volume 43 (2020)
Volume Volume 42 (2019)
Volume Volume 41 (2018)
Volume Volume 40 (2017)
Hassan, R., Kamar, S., Marzouk, S., Rashed, L., Mohamed, E., Gharib, D., Goda, M. (2022). Microvesicles Therapy with Melatonin in Targeting Mitochondrial Dysfunction in Alzheimer''''s Disease Model of Female Albino Rats: Histological and Biochemical Study. Egyptian Journal of Histology, 45(2), 514-530. doi: 10.21608/ejh.2021.69213.1450
Rokia Mohamad Hassan; Samaa Samir Kamar; Samar Marzouk; Laila Rashed; Eman Mohamed; Doaa Mostafa Gharib; Mai Abd Alaziz Goda. "Microvesicles Therapy with Melatonin in Targeting Mitochondrial Dysfunction in Alzheimer''''s Disease Model of Female Albino Rats: Histological and Biochemical Study". Egyptian Journal of Histology, 45, 2, 2022, 514-530. doi: 10.21608/ejh.2021.69213.1450
Hassan, R., Kamar, S., Marzouk, S., Rashed, L., Mohamed, E., Gharib, D., Goda, M. (2022). 'Microvesicles Therapy with Melatonin in Targeting Mitochondrial Dysfunction in Alzheimer''''s Disease Model of Female Albino Rats: Histological and Biochemical Study', Egyptian Journal of Histology, 45(2), pp. 514-530. doi: 10.21608/ejh.2021.69213.1450
Hassan, R., Kamar, S., Marzouk, S., Rashed, L., Mohamed, E., Gharib, D., Goda, M. Microvesicles Therapy with Melatonin in Targeting Mitochondrial Dysfunction in Alzheimer''''s Disease Model of Female Albino Rats: Histological and Biochemical Study. Egyptian Journal of Histology, 2022; 45(2): 514-530. doi: 10.21608/ejh.2021.69213.1450

Microvesicles Therapy with Melatonin in Targeting Mitochondrial Dysfunction in Alzheimer''''s Disease Model of Female Albino Rats: Histological and Biochemical Study

Article 13, Volume 45, Issue 2, June 2022, Page 514-530  XML PDF (4.22 MB)
Document Type: Original Article
DOI: 10.21608/ejh.2021.69213.1450
View on SCiNiTO View on SCiNiTO
Authors
Rokia Mohamad Hassan email orcid 1; Samaa Samir Kamar2; Samar Marzouk3; Laila Rashed4; Eman Mohamed5; Doaa Mostafa Gharib6; Mai Abd Alaziz Goda6
1Histology and cell biology Department, Faculty of Medicine, Cairo University
2Histology and cell biology department, faculty of medicine, Cairo university
3Medical biochemistry and molecular biology department,faculty of medicine, Cairo university
4Medical Biochemistry and molecular biology department,Faculty of Medicine, Cairo University
5Medical biochemistry and cell biology department, faculty of medicine, Cairo university
6Medical biochemistry and molecular biology department, faculty of medicine, Cairo university
Abstract
Background and Objectives: Alzheimer''s disease (AD) is a progressive neurodegenerative disease that causes cognitive impairment.
The Aim of this Study: Was to evaluate microvesicles (MVs) and melatonin effects on mitochondrial biogenesis and apoptosis in an experimental model of Alzheimer''s disease in rats
Methods: Forty-five female rats were divided randomly (9 rats in each group) intoGpI (control) and experimental groups, which included: GpII (AD), GpIII (AD+MVs), GpIV (AD+melatonin), GpV (AD+MVs+melatonin). Induction of AD was done by a single intraperitoneali.p injection of lipopolysaccharide (LPS) of 0.8mg/kg. One week after the AD induction, the treated groups received a single i.p injection of MVs at a dose of 0.2mg/kg or melatonin by i.p injection of 10mg/kg once daily for three weeks or combined therapy of both. When the experiment was over, Y-maze & open field tests were used to assess the cognitive functions. The hippocampus was subjected to histological and immunohistochemical studies for assessment of the morphological changes. Besides, biochemical investigations were performed for AD pathogenesis, mitochondrial biogenesis, inflammatory mediators, and apoptosis.
Results: The AD modeling group demonstrated impaired cognitive function, a significant increase in AD markers; Aβ plaques deposition in Congo-red stained sections and the levels of Aβ-42 and p-tau protein, increased apoptotic markers; Casp-3 positive immunostaining and Cyt-c level, a significant reduction in mitochondrial biogenesis markers; gene expressions of PGC-1α, Nrf-2, TFAM and Sirt-1, affection of the brain energy metabolism represented by the AMPK level. Besides, the IL-6 level increased significantly. The therapy with MVs, melatonin, or combined therapy had a curative role against AD with the best results in the combined therapy group.
Conclusion: Combined therapy with MVs and melatonin was superior to single therapy for AD.
Keywords
Aβ- plaques; alzheimer''s disease; casp-3; melatonin; microvesicles
Statistics
Article View: 959
PDF Download: 882
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.